I did not make that up. Any who works with cell lines knows that contamination is a constant problem. There are techniques to reduce contamination, but there are not any full proof methods to prevent it.
“Each manufacturing run of GRNOPC1 is subjected to standardized quality control testing to ensure viability, sterility and appropriate cellular composition before release for clinical use. “
They do quality control because there is ALWAYS the potential for cell lines to become contaminated. Again, anyone who works with cell lines knows this.
“The existing master cell bank could potentially supply sufficient starting material for GRNOPC1 to commercially supply the U.S. acute spinal cord injury market for more than 20 years.”
This sounds like some sort of PR release from the company. Their claim that they have a 20 year supply is not a scientifically proven fact, it is just a prediction. Notice how they use the words “could potentially supply.”
Remember, this is from a biotech company that wants to sell their product. This does not include any of the original data that was used to make this claim.
Your accusation that “I just made that up” is wrong.
Of course there’s potential. Read what I wrote...I specified practicality.
And of course that verbiage I posted was meant to encourage investors.